Isofol Medical New data in line with expectations
The company has reported efficacy data from 19 patients with advanced colorectal cancer who are enrolled in an extension arm of the ongoing phase I/IIa study ISO-CC-005. Nine of 19 (47%) patients experienced a reduction in tumour size of at least 20%; this was largely in line with our expectations. About a year ago, the company reported data from 12 other patients who had been treated with arfolitixorin; in this readout, seven of 12 (c58%) patients experienced a reduction in tumour size of at least 20%. Note that patients did not receive the same treatment combination that is being evaluated in the phase III study (AGENT).
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.